NImmune Biopharma Launches Clinical Program for NIM-1324 to Treat Inflammatory Bowel Diseases

New data shows NIM-1324 outperforms current IBD medications and establishes Phase 1 safety and tolerability.

Published on Feb. 18, 2026

Got story updates? Submit your updates here. ›

NImmune Biopharma, a private late-stage precision inflammation and immunology biopharmaceutical company, announced that its Executive Chairman, President and CEO Dr. Josep Bassaganya-Riera will be launching a new clinical program and business venture to develop NIM-1324 as its lead asset focused on inflammatory bowel disease (IBD), with follow-on indications for other inflammatory and autoimmune diseases. NIM-1324 is an investigational, oral, once-daily, small molecule LANCL2 therapeutic that has demonstrated favorable safety and tolerability in its first-in-human clinical trial.

Why it matters

NIM-1324's novel mechanism of action targeting the LANCL2 pathway offers first-in-class potential for treating IBD, including ulcerative colitis and Crohn's disease, by selectively enhancing anti-inflammatory responses to support clinical remission and mucosal healing without the broad immune suppression and adverse side effects of current IBD treatments.

The details

NIM-1324 is a derisked, safe and well-tolerated, oral, once-daily, small molecule LANCL2 therapeutic that leverages biomarker-driven precision immunology and a novel immunometabolic mechanism aimed at activating regulatory T cells to re-establish immune tolerance at sites of inflammation. In its first-in-human clinical trial, NIM-1324 met all primary and secondary endpoints, demonstrated a favorable safety profile with no dose limiting toxicities, and showed improved pharmacokinetics.

  • NIM-1324's first-in-patient ulcerative colitis study will be launched following the presentation of new research findings at Digestive Disease Week 2026.
  • The NIMML Institute will present two abstracts on NIM-1324 at Digestive Disease Week 2026.

The players

NImmune Biopharma

A private late-stage precision inflammation and immunology biopharmaceutical company that leverages a proprietary A.I. platform to develop novel immunoregulatory therapeutics.

Dr. Josep Bassaganya-Riera

The Executive Chairman, President and CEO of NImmune Biopharma who is launching the new clinical program and business venture to develop NIM-1324.

NIMML Institute

A 501(c)(3) non-profit foundation dedicated to combining advanced computational modeling using A.I. with translational research and clinical testing to accelerate development of precision medicines for inflammatory and autoimmune diseases.

Got photos? Submit your photos here. ›

What they’re saying

“I am eager to launch my latest business venture for the clinical development of NIM-1324 and continue building on the incredible successes addressing unmet clinical needs of patients we've seen across the LANCL2 therapeutic portfolio.”

— Dr. Josep Bassaganya-Riera, Executive Chairman, President and CEO, NImmune Biopharma (Business Wire)

“Through its unique and clinically validated novel mechanism of action, NIM-1324 selectively enhances anti-inflammatory responses that safely support clinical remission and mucosal healing, as opposed to current IBD treatments that broadly suppress the immune system and result in significant adverse side effects.”

— Dr. Josep Bassaganya-Riera, Executive Chairman, President and CEO, NImmune Biopharma (Business Wire)

What’s next

A well-powered, proof-of-concept Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo in moderate-to-severe ulcerative colitis patients to evaluate clinical remission and target engagement.

The takeaway

NIM-1324's novel mechanism of action targeting the LANCL2 pathway offers a promising new approach to treating inflammatory bowel diseases like ulcerative colitis and Crohn's disease, with the potential to provide symptom relief and improve outcomes for patients without the side effects of current treatments.